How SCFAs modulate cardiometabolic disease risk by interacting with an individual’s adiposity parameters and diet.
DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval
DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.